0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Thoracic Radiotherapy Does Not Prolong Survival in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer

David H. Johnson, MD; Lawrence H. Einhorn, MD; Alfred Bartolucci, PhD; Robert Birch, PhD; George Omura, MD; Carlos A. Perez, MD; and F. Anthony Greco, MD
[+] Article and Author Information

Grant Support: In part by grants CA28171; CA39844; CA15584; CA23909; CA28169; CA07961; CA03227; CA05641; CA12223; CA20255; CA13237; CA28138; CA0313; CA19657; CA24456; CA03376; and CA28143 from the National Cancer Institute.

Requests for Reprints: David H. Johnson, MD, Division of Medical Oncology, 1956 The Vanderbilt Clinic, Nashville, TN 37232-5536.

Current Author Addresses: Drs. Johnson and Greco: 1956 The Vanderbilt Clinic, Nashville, TN 37232.

Dr. Einhorn: Room A109, University Hospital, Indianapolis, IN 46223.Dr. Bartolucci: LBW Tumor Institute, Rm G-01, Birmingham, AL 35294.

Dr. Birch: Biological Therapy Institute, Franklin, TN 37064.

Dr. Omura: Division of Hematology/Oncology, Birmingham, AL 35294.

Dr. Perez: Mallinckrodt Institute, 510 South King Highway, St. Louis, MO 63110.


© 1990 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1990;113(1):33-38. doi:10.7326/0003-4819-113-1-33
Text Size: A A A

Study Objective: To compare the survival of patients with locally advanced non-small cell lung cancer treated with single-agent vindesine, thoracic radiotherapy, or both treatment modalities.

Design: Randomized, prospective, phase III trial.

Setting: Multi-institutional, university-based national cooperative oncology group.

Patients: The study included 319 patients with locally advanced, unresectable non-small cell lung cancer who had no evidence of extrathoracic metastases. All patients were ambulatory and had measurable disease. Some patients could not have surgery because of coexisting medical conditions.

Intervention: Patients were randomly assigned to receive vindesine, 3 mg/m2 body surface area weekly; standard thoracic radiotherapy, 60 Gy over 6 weeks; or both vindesine and thoracic radiotherapy. Vindesine was administered for 6 weeks and then every other week to patients who had no disease progression. Patients who developed progressive disease while receiving vindesine or radiotherapy alone were crossed over to radiotherapy or vindesine, respectively. Response assessment took place at week 6.

Results: The overall response rate was superior in the radiotherapy arms (radiotherapy alone, 30%; radiotherapy plus vindesine, 34%; vindesine alone, 10%; P = 0.001). However, with a minimum follow-up of 42 months, no improvement in survival has been seen with radiotherapy. The median survival was 8.6 months for patients receiving radiotherapy alone, 9.4 months for those receiving radiotherapy plus vindesine, and 10.1 months for those receiving vindesine (P = 0.58). Radiotherapy also failed to improve long-term survival. The 5-year survivals were 3%, 3%, and 1%, respectively (P = 0.56).

Conclusion: Patients with non-small cell lung cancer who have inoperable, nonmetastatic disease gain no clinically meaningful survival advantage with immediate thoracic irradiation, even when modern megavoltage radiation therapy techniques and equipment are used.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)